111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: Its accuracy and prognostic significance

Giovenzio Genestreti, Alberto Bongiovanni, Marco Angelo Burgio, Salvatore Luca Burgio, Alessandra Musto, Alice Rossi, Manuela Monti, Emanuela Scarpi, Paola Ulivi, Sara Bravaccini, Alessandra Dubini, Federica Matteucci, Giampaolo Gavelli

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Small-cell lung cancer (SCLC) may express somatostatin transmembrane receptors (SSTRs) in 50-75% of cases. We evaluated the accuracy and prognostic significance of somatostatin receptor scintigraphy (SSRS) in staging compared with conventional radiological procedures.

PATIENTS AND METHODS: Newly diagnosed SCLC patients underwent scintigraphy with the radiolabeled somatostatin analog indium-111 (111In)-pentetreotide (OctreoScan). Histological data were available for 20 (38%) patients for immunohistochemical analysis of SSTR-2 expression.

RESULTS: From May 2007 to December 2011 we analyzed 52 SCLC patients. In comparison with standard radiologic staging, the sensitivity and specificity of SSRS were 63 and 100% for primary pulmonary tumor (T), 51 and 100% for mediastinal lymph node (N), and 23 and 91% for metastatic disease (M), respectively. The overall SSRS accuracy was 65% for T, 62% for N, and 52% for M. Patients with positive SSRS achieved a disease control rate of 97 versus 84% in those with negative exam results; median progression-free survival was 9.5 months versus 11.0 and median overall survival was 15.3 versus 14.5 months for patients with positive SSRS versus those with a negative result. Notably, seven (78%) patients with a positive quantitative analysis for SSTR-2 had a positive SSRS; at semiquantitative analysis this correlation was found in eight (73%) patients.

CONCLUSION: SSRS has a lower accuracy in comparison with standard radiological staging in SCLC. However, patients with a positive SSRS given standard treatments showed better disease control compared with those with a negative SSRS, but similar progression-free survival and overall survival.

Original languageEnglish
Pages (from-to)135-142
Number of pages8
JournalNuclear Medicine Communications
Volume36
Issue number2
DOIs
Publication statusPublished - Feb 3 2015

Fingerprint

Somatostatin Receptors
Small Cell Lung Carcinoma
Radionuclide Imaging
Disease-Free Survival
pentetreotide
Survival
Somatostatin
Lymph Nodes
Sensitivity and Specificity

Keywords

  • accuracy
  • chemotherapy
  • octreotide
  • small-cell lung cancer
  • somatostatin
  • uptake

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

@article{0afd1146f3304c27a66bc596933ae9df,
title = "111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: Its accuracy and prognostic significance",
abstract = "BACKGROUND: Small-cell lung cancer (SCLC) may express somatostatin transmembrane receptors (SSTRs) in 50-75{\%} of cases. We evaluated the accuracy and prognostic significance of somatostatin receptor scintigraphy (SSRS) in staging compared with conventional radiological procedures.PATIENTS AND METHODS: Newly diagnosed SCLC patients underwent scintigraphy with the radiolabeled somatostatin analog indium-111 (111In)-pentetreotide (OctreoScan). Histological data were available for 20 (38{\%}) patients for immunohistochemical analysis of SSTR-2 expression.RESULTS: From May 2007 to December 2011 we analyzed 52 SCLC patients. In comparison with standard radiologic staging, the sensitivity and specificity of SSRS were 63 and 100{\%} for primary pulmonary tumor (T), 51 and 100{\%} for mediastinal lymph node (N), and 23 and 91{\%} for metastatic disease (M), respectively. The overall SSRS accuracy was 65{\%} for T, 62{\%} for N, and 52{\%} for M. Patients with positive SSRS achieved a disease control rate of 97 versus 84{\%} in those with negative exam results; median progression-free survival was 9.5 months versus 11.0 and median overall survival was 15.3 versus 14.5 months for patients with positive SSRS versus those with a negative result. Notably, seven (78{\%}) patients with a positive quantitative analysis for SSTR-2 had a positive SSRS; at semiquantitative analysis this correlation was found in eight (73{\%}) patients.CONCLUSION: SSRS has a lower accuracy in comparison with standard radiological staging in SCLC. However, patients with a positive SSRS given standard treatments showed better disease control compared with those with a negative SSRS, but similar progression-free survival and overall survival.",
keywords = "accuracy, chemotherapy, octreotide, small-cell lung cancer, somatostatin, uptake",
author = "Giovenzio Genestreti and Alberto Bongiovanni and Burgio, {Marco Angelo} and Burgio, {Salvatore Luca} and Alessandra Musto and Alice Rossi and Manuela Monti and Emanuela Scarpi and Paola Ulivi and Sara Bravaccini and Alessandra Dubini and Federica Matteucci and Giampaolo Gavelli",
year = "2015",
month = "2",
day = "3",
doi = "10.1097/MNM.0000000000000221",
language = "English",
volume = "36",
pages = "135--142",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - 111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer

T2 - Its accuracy and prognostic significance

AU - Genestreti, Giovenzio

AU - Bongiovanni, Alberto

AU - Burgio, Marco Angelo

AU - Burgio, Salvatore Luca

AU - Musto, Alessandra

AU - Rossi, Alice

AU - Monti, Manuela

AU - Scarpi, Emanuela

AU - Ulivi, Paola

AU - Bravaccini, Sara

AU - Dubini, Alessandra

AU - Matteucci, Federica

AU - Gavelli, Giampaolo

PY - 2015/2/3

Y1 - 2015/2/3

N2 - BACKGROUND: Small-cell lung cancer (SCLC) may express somatostatin transmembrane receptors (SSTRs) in 50-75% of cases. We evaluated the accuracy and prognostic significance of somatostatin receptor scintigraphy (SSRS) in staging compared with conventional radiological procedures.PATIENTS AND METHODS: Newly diagnosed SCLC patients underwent scintigraphy with the radiolabeled somatostatin analog indium-111 (111In)-pentetreotide (OctreoScan). Histological data were available for 20 (38%) patients for immunohistochemical analysis of SSTR-2 expression.RESULTS: From May 2007 to December 2011 we analyzed 52 SCLC patients. In comparison with standard radiologic staging, the sensitivity and specificity of SSRS were 63 and 100% for primary pulmonary tumor (T), 51 and 100% for mediastinal lymph node (N), and 23 and 91% for metastatic disease (M), respectively. The overall SSRS accuracy was 65% for T, 62% for N, and 52% for M. Patients with positive SSRS achieved a disease control rate of 97 versus 84% in those with negative exam results; median progression-free survival was 9.5 months versus 11.0 and median overall survival was 15.3 versus 14.5 months for patients with positive SSRS versus those with a negative result. Notably, seven (78%) patients with a positive quantitative analysis for SSTR-2 had a positive SSRS; at semiquantitative analysis this correlation was found in eight (73%) patients.CONCLUSION: SSRS has a lower accuracy in comparison with standard radiological staging in SCLC. However, patients with a positive SSRS given standard treatments showed better disease control compared with those with a negative SSRS, but similar progression-free survival and overall survival.

AB - BACKGROUND: Small-cell lung cancer (SCLC) may express somatostatin transmembrane receptors (SSTRs) in 50-75% of cases. We evaluated the accuracy and prognostic significance of somatostatin receptor scintigraphy (SSRS) in staging compared with conventional radiological procedures.PATIENTS AND METHODS: Newly diagnosed SCLC patients underwent scintigraphy with the radiolabeled somatostatin analog indium-111 (111In)-pentetreotide (OctreoScan). Histological data were available for 20 (38%) patients for immunohistochemical analysis of SSTR-2 expression.RESULTS: From May 2007 to December 2011 we analyzed 52 SCLC patients. In comparison with standard radiologic staging, the sensitivity and specificity of SSRS were 63 and 100% for primary pulmonary tumor (T), 51 and 100% for mediastinal lymph node (N), and 23 and 91% for metastatic disease (M), respectively. The overall SSRS accuracy was 65% for T, 62% for N, and 52% for M. Patients with positive SSRS achieved a disease control rate of 97 versus 84% in those with negative exam results; median progression-free survival was 9.5 months versus 11.0 and median overall survival was 15.3 versus 14.5 months for patients with positive SSRS versus those with a negative result. Notably, seven (78%) patients with a positive quantitative analysis for SSTR-2 had a positive SSRS; at semiquantitative analysis this correlation was found in eight (73%) patients.CONCLUSION: SSRS has a lower accuracy in comparison with standard radiological staging in SCLC. However, patients with a positive SSRS given standard treatments showed better disease control compared with those with a negative SSRS, but similar progression-free survival and overall survival.

KW - accuracy

KW - chemotherapy

KW - octreotide

KW - small-cell lung cancer

KW - somatostatin

KW - uptake

UR - http://www.scopus.com/inward/record.url?scp=84920433642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920433642&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000000221

DO - 10.1097/MNM.0000000000000221

M3 - Article

C2 - 25321157

AN - SCOPUS:84920433642

VL - 36

SP - 135

EP - 142

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 2

ER -